Michael C. Donohue

Michael C. Donohue

Auto-generated profile, based on publicly available information

Michael C. Donohue

Alzheimer’s Therapeutic Research Institute, University of Southern California, San Diego, CA, USA

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2010 in Neurology
Verified
Journal Article
Closed access
PDF file
RPR. C. Petersen
R. C. Petersen
PAP. S. Aisen
P. S. Aisen
LBL. A. Beckett
L. A. Beckett
MDM. C. Donohue
M. C. Donohue
AGA. C. Gamst
A. C. Gamst
MWM. W. Weiner
M. W. Weiner
Background: Neuroimaging measures and chemical biomarkers may be important indices of clinical progression in normal aging and mild cognitive impairment (MCI) and need to be evaluated longitudinally. Objective: To characterize cross-sectionally and longitudinally clinical measures in normal controls, subjects with MCI, and subjects with mild Alzheimer disease (AD) to enable the assessment of the utility of neuroimaging and chemical biomarker measures. Methods: A total of 819 subjects (229 cognitively normal, 398 with MCI, and 192 with AD) were enrolled at baseline and followed for 12 months using standard cognitive and functional measures typical of clinical trials. Results: The subjects with MCI were more memory impaired than the cognitively normal subjects but not as impaired as the subjects with AD. Nonmemory cognitive measures were only minimally impaired in the subjects with MCI. The subjects with MCI progressed to dementia in 12 months at a rate of 16.5% per year. Approximately 50% of the subjects with MCI were on antidementia therapies. There was minimal movement on the Alzheimer9s Disease Assessment Scale–Cognitive Subscale for the normal control subjects, slight movement for the subjects with MCI of 1.1, and a modest change for the subjects with AD of 4.3. Baseline CSF measures of Aβ-42 separated the 3 groups as expected and successfully predicted the 12-month change in cognitive measures. Conclusion: The Alzheimer9s Disease Neuroimaging Initiative has successfully recruited cohorts of cognitively normal subjects, subjects with mild cognitive impairment (MCI), and subjects with Alzheimer disease with anticipated baseline characteristics. The 12-month progression rate of MCI was as predicted, and the CSF measures heralded progression of clinical measures over 12 months.

1 August 2014 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
MDMichael C. Donohue
Michael C. Donohue
RSReisa A. Sperling
Reisa A. Sperling
DSDavid P. Salmon
David P. Salmon
DRDorene M. Rentz
Dorene M. Rentz
RRRema Raman
Rema Raman
BIBiomarkers For The Australian Imaging
Biomarkers For The Australian Imaging
The field of Alzheimer disease (AD) research has evolved to conceptualize AD as a continuum of disease.1-4 Although, historically, AD was considered to begin with the onset of dementia, a predementia stage, characterized clinically as mild cognitive impairment and, more specifically, using biomarkers, as prodromal AD, has been widely accepted.5-7 Most recently, the preclinical stage of AD has been postulated. This asymptomatic stage, believed to precede mild cognitive impairment by years, is characterized by accumulating amyloid pathology and neurodegeneration accompanied by very subtle cognitive decline detectable with sensitive neuropsychological tests and cognitive complaint measures.1 Individuals with preclinical AD (ie, cognitively normal individuals with biomarker evidence of brain amyloid deposition) represent a group at high risk for decline and an ideal population for a “secondary prevention” trial aimed at delaying the emergence of the clinical syndromes of mild cognitive impairment and dementia.8

1 May 2010 in Alzheimer's & Dementia
Verified
Journal Article
Closed access
PAPaul S. Aisen
Paul S. Aisen
RPRonald C. Petersen
Ronald C. Petersen
MDMichael C. Donohue
Michael C. Donohue
AGAnthony Gamst
Anthony Gamst
RRRema Raman
Rema Raman
AIAlzheimer'S Disease Neuroimaging Initiative
Alzheimer'S Disease Neuroimaging Initiative

13 June 2017 in JAMA
Verified
Journal Article
Open access
PDF file
MDMichael C. Donohue
Michael C. Donohue
RSReisa A. Sperling
Reisa A. Sperling
RPRonald Petersen
Ronald Petersen
CSChung-Kai Sun
Chung-Kai Sun
MWMichael W. Weiner
Michael W. Weiner
FIFor The Alzheimer’s Disease Neuroimaging Initiative
For The Alzheimer’s Disease Neuroimaging Initiative
Quiz Ref ID Clinical diagnosis of Alzheimer disease (AD) has required the syndrome of dementia with impairment of multiple cognitive domains sufficient to interfere with performance of daily activities. Dementia is preceded by the syndrome of mild cognitive impairment (MCI) with symptoms and objective evidence of cognitive impairment but with preservation of function. Biomarkers of AD pathology, particularly amyloid positron emission tomography (PET) or cerebrospinal fluid (CSF) evidence of brain amyloid, allow specific identification of individuals with MCI likely to progress to AD dementia. MCI accompanied by such biomarker abnormalities is now considered to be prodromal AD.1

24 March 2014 in Alzheimer's & Dementia
Verified
Journal Article
Closed access
MDMichael C. Donohue
Michael C. Donohue
HJHélène Jacqmin‐Gadda
Hélène Jacqmin‐Gadda
MGMélanie Le Goff
Mélanie Le Goff
RTRonald G. Thomas
Ronald G. Thomas
RRRema Raman
Rema Raman
PAPaul S. Aisen
Paul S. Aisen

1 July 2015 in Alzheimer's & Dementia
Verified
Journal Article
Closed access
PAPaul S. Aisen
Paul S. Aisen
RPRonald C. Petersen
Ronald C. Petersen
MDMichael Donohue
Michael Donohue
MWMichael W. Weiner
Michael W. Weiner
AIAlzheimer'S Disease Neuroimaging Initiative
Alzheimer'S Disease Neuroimaging Initiative